MRK insider filings
Merck & Co., Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-16. Screen MRK transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 58,185 shares, $8,611,875 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 58,185 shares @ $148.01 ($8,611,875) by DeLuca Richard R., filed 2026-11-16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | 1 | — | 1 leg · 58,185 sh · $8,611,875 | 2 |
| Coe Mary Ellen — Director | 1 | — | — | 1 |
| DIAZ PAUL J — Director | 2 | — | — | 1 |
| Karsanbhai Surendralal Lanca — Director | 1 | — | — | 1 |
| Seidman Christine E — Director | 1 | — | — | 1 |
| Maraldo David R. — EVP & Pres. MMD | 1 | — | — | — |
Recent insider filings — Merck & Co., Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-16 | 4 | DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | Option exercise (M): 58,185 @ $77.62 · Sale (S): 58,185 @ $148.01 · Option exercise (M): 58,185 (derivative) @ $0 | EDGAR |
| 2026-11-03 | 4 | DIAZ PAUL J — Director | Grant/award (A): 613.07 (derivative) @ $149.52 | EDGAR |
| 2026-11-03 | 3 | DIAZ PAUL J — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3/A | Maraldo David R. — EVP & Pres. MMD | Holdings only — no transactions reported | EDGAR |
| 2026-10-01 | 4 | Seidman Christine E — Director | Grant/award (A): 55.91 (derivative) @ $145.31 | EDGAR |
| 2026-10-01 | 4 | Karsanbhai Surendralal Lanca — Director | Grant/award (A): 111.83 (derivative) @ $145.31 | EDGAR |
| 2026-10-01 | 4 | Coe Mary Ellen — Director | Grant/award (A): 206.46 (derivative) @ $145.31 | EDGAR |
| 2026-08-13 | 4 | Guindo Chirfi — EVP, Access, Policy & Comms | Sale (S): 10,000 @ $135 | EDGAR |
| 2026-08-13 | 4 | Zachary Jennifer — EVP, General Counsel | Option exercise (M): 41,494 @ $117.89 · Option exercise (M): 13,433 @ $84.71 · Sale (S): 80,315 @ $133.46 · Option exercise (M): 41,494 (derivative) @ $0 · Option exercise (M): 13,433 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | Sale (S): 20,784 @ $130.43 · Sale (S): 7,410 @ $131.33 · Sale (S): 5,427 @ $132.35 · Sale (S): 11,099 @ $131.61 · Sale (S): 600 @ $132.04 | EDGAR |
| 2026-08-10 | 4 | DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | Sale (S): 805 @ $131.02 · Sale (S): 4,945 @ $130.23 · Sale (S): 300 @ $131.02 | EDGAR |
| 2026-08-07 | 4 | Maraldo David R. — EVP & Pres. MMD | Option exercise (M): 6,311 @ $73.73 · Sale (S): 6,311 @ $128.72 · Option exercise (M): 9,709 @ $87.10 · Sale (S): 9,709 @ $128.72 · Option exercise (M): 2,686 @ $84.71 · Sale (S): 2,686 @ $128.72 · +3 more | EDGAR |
| 2026-08-07 | 4 | Guindo Chirfi — EVP, Access, Policy & Comms | Sale (S): 15,000 @ $131 | EDGAR |
| 2026-08-07 | 4 | Williams David Michael — EVP,Chief Info&Digital Officer | Option exercise (M): 4,600 @ $77.62 · Sale (S): 4,600 @ $128.77 · Option exercise (M): 13,542 @ $75.36 · Sale (S): 13,542 @ $128.77 · Option exercise (M): 34,705 @ $73.73 · Sale (S): 34,705 @ $128.77 · +3 more | EDGAR |
| 2026-07-01 | 4 | Seidman Christine E — Director | Grant/award (A): 63.23 (derivative) @ $128.50 | EDGAR |
| 2026-07-01 | 4 | Karsanbhai Surendralal Lanca — Director | Grant/award (A): 126.46 (derivative) @ $128.50 | EDGAR |
| 2026-07-01 | 4 | Coe Mary Ellen — Director | Grant/award (A): 233.46 (derivative) @ $128.50 | EDGAR |
| 2026-06-02 | 4 | Mayo Stephen — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Seidman Christine E — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Karsanbhai Surendralal Lanca — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Coe Mary Ellen — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Rothman Paul — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Warden Kathy J — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | THULIN INGE G — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | Craig Pamela J. — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | BAKER DOUGLAS M JR — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | GLOCER THOMAS H — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | LAVIZZO-MOUREY RISA J — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-06-02 | 4 | RUSSO PATRICIA F — Director | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-05-07 | 4 | Maraldo David R. — EVP & Pres. MMD | Grant/award (A): 7,424 (derivative) @ $0 · Grant/award (A): 21,731 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Foard Brian — EVP, Specialty, Pharma, & ID | Grant/award (A): 10,605 (derivative) @ $0 · Grant/award (A): 35,351 (derivative) @ $0 · Grant/award (A): 31,044 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Smart Dalton E. III — SVP Fin. - Global Controller | Grant/award (A): 2,298 (derivative) @ $0 · Grant/award (A): 5,045 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Oosthuizen Johannes Jacobus — EVP, Oncology & Int?l | Grant/award (A): 10,605 (derivative) @ $0 · Grant/award (A): 31,044 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Litchfield Caroline — EVP & CFO | Grant/award (A): 15,908 (derivative) @ $0 · Grant/award (A): 46,566 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Li Dean Y — Executive VP & President, MRL | Grant/award (A): 19,885 (derivative) @ $0 · Grant/award (A): 58,207 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Williams David Michael — EVP,Chief Info&Digital Officer | Grant/award (A): 4,640 (derivative) @ $0 · Grant/award (A): 13,582 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Zachary Jennifer — EVP, General Counsel | Grant/award (A): 12,064 (derivative) @ $0 · Grant/award (A): 35,312 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Guindo Chirfi — EVP, Access, Policy & Comms | Grant/award (A): 6,628 (derivative) @ $0 · Grant/award (A): 19,402 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Larson Betty D — EVP, Chief HR Officer | Grant/award (A): 7,954 (derivative) @ $0 · Grant/award (A): 23,283 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | Grant/award (A): 11,931 (derivative) @ $0 · Grant/award (A): 34,924 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Davis Robert M — Chairman, CEO & President, Director | Grant/award (A): 47,724 (derivative) @ $0 · Grant/award (A): 139,697 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Maraldo David R. — EVP & Pres. MMD | Option exercise (M): 552 @ $112.16 · Tax withholding (F): 159 @ $112.16 · Option exercise (M): 552 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Smart Dalton E. III — SVP Fin. - Global Controller | Option exercise (M): 383 @ $112.16 · Tax withholding (F): 132 @ $112.16 · Option exercise (M): 383 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Williams David Michael — EVP,Chief Info&Digital Officer | Option exercise (M): 1,377 @ $110.03 · Tax withholding (F): 679 @ $110.03 · Option exercise (M): 1,377 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Zachary Jennifer — EVP, General Counsel | Option exercise (M): 2,951 @ $110.03 · Tax withholding (F): 1,454 @ $110.03 · Option exercise (M): 2,951 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Guindo Chirfi — EVP, Access, Policy & Comms | Option exercise (M): 1,967 @ $110.03 · Tax withholding (F): 969 @ $110.03 · Option exercise (M): 1,967 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Chattopadhyay Sanat — Exe V-P & Pres. MMD | Option exercise (M): 2,597 @ $110.03 · Tax withholding (F): 1,130 @ $110.03 · Option exercise (M): 2,597 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Larson Betty D — EVP, Chief HR Officer | Option exercise (M): 2,085 @ $110.03 · Tax withholding (F): 715 @ $110.03 · Option exercise (M): 11,350 @ $110.95 · Tax withholding (F): 5,143 @ $110.95 · Option exercise (M): 2,085 (derivative) @ $0 · Option exercise (M): 11,350 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | DeLuca Richard R. — EVP&Pres, Merck Animal Heallth | Option exercise (M): 2,518 @ $110.03 · Tax withholding (F): 1,241 @ $110.03 · Option exercise (M): 2,518 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Davis Robert M — Chairman, CEO & President, Director | Option exercise (M): 13,300 @ $110.03 · Tax withholding (F): 6,551 @ $110.03 · Option exercise (M): 13,300 (derivative) @ $0 | EDGAR |
Recent 8-K events — Merck & Co., Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MRK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs